研究指Moderna疫苗產生抗體量遠高於復必泰
《美國醫學會雜誌》刊登一項於比利時進行的研究,發現Moderna(MRNA.US)生產的新冠疫苗,較輝瑞(PFE.US)及BioNTech(BNTX.US)研發的「復必泰」疫苗產生更多抗體。
研究調查2,499名比利時健康護理人員,他們均完成接種疫苗,結果顯示在曾感染新冠及未曾感染新冠羣組中,接種Moderna疫苗人士體內抗體均高於接種「復必泰」人士。其中在未曾感染新冠羣組中,接種Moderna疫苗人士的抗體量爲每毫升2,881個單位,接種「復必泰」的則爲每毫升1,108個單位。
研究指出抗體水平相差甚遠的可能原因,包括接種兩劑Moderna疫苗相隔時間爲四周,較「復必泰」相隔時間多一週,及Moderna疫苗的主要活躍成分濃度較高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.